Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Florbetaben
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : pharmtrace
Deal Size : Inapplicable
Deal Type : Inapplicable
Test-retest Study With [18F]FBB in Cardiac Amyloidosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 24, 2025
Lead Product(s) : Florbetaben
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : pharmtrace
Deal Size : Inapplicable
Deal Type : Inapplicable
[18F]PI-2620 Phase 3 Histopathological Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
December 08, 2022
Lead Product(s) : 18-F PI-2620
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Walter Reed National Military Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
April 20, 2022
Lead Product(s) : 18-F PI-2620
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Walter Reed National Military Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Test-retest Study With [18F]PI-2620 in PSP-RS and NDC
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
January 12, 2022
Lead Product(s) : 18-F Florbetaben
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : pharmtrace klinische Entwicklung
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
January 11, 2022
Lead Product(s) : 18-F Florbetaben
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : pharmtrace klinische Entwicklung
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 18-F PI2620
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Life Molecular Imaging
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
January 20, 2021
Lead Product(s) : 18-F PI2620
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Life Molecular Imaging
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
August 24, 2015
Lead Product(s) : 68-Ga RM2
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
June 29, 2015
Lead Product(s) : 68-Ga RM2
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 18-F GP1
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Recipient : University of Zurich
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of a New Imagingtechnologie for Thrombosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
June 11, 2015
Lead Product(s) : 18-F GP1
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Recipient : University of Zurich
Deal Size : Inapplicable
Deal Type : Inapplicable
PET Imaging of Intracranial Cancers With 18F-FSPG
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
February 25, 2015